Global Health Ventures Inc. (OTCBB:GHLV) Commences an Investment Road Show, Starting in Montreal, Quebec and Then Presenting in London, England - Merck & Co (NYSE:MRK)

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 6, 2009) - Global Health Ventures Inc. or the "Company" GHLV, a Specialty Pharma, is pleased to announce that they are about to begin an investment road show, starting in Montreal, Quebec this week, and then presenting in London, England.

Global Health is raising via a Private Placement proceeds of up to $2,000,000 USD. The Company is currently negotiating the terms of the investment, and although there is no guarantee, management is quite confident of success. The Company will use the proceeds of this financing to carry out the clinical trials needed for approval of its lead life-style pharmaceutical product, (X-Excite), a male sexual enhancement drug. X-Excite is a new formulation of an existing sexual enhancement drug, which is designed to rapidly enter the blood system, maximizing its efficacy and performance. The drug is developed to work sublingually, thus having a more rapid mode of action, and bypassing all the inconveniences and many side effects associated with other application routes.

"Our new platform technology allows us to deliver many already approved drugs sublingually (under the tongue) thus avoiding many side effects these drugs may have, yet maintain the products efficacy. Major pharmaceutical companies are facing a steep revenue decline because of looming patent expirations and lack of innovation for new drugs. Specialty Pharma's and biotech companies are becoming highly desirable due to their pipeline of new drugs and solid innovations," said Dr. Hassan Salari, President & CEO.

Previous to his entrepreneurial ventures, Dr. Salari served as a consultant and advisor to Merk MRK, Beecham (now Glaxo, NYSE: GSX), Rhone Poulenc (now Sanofi-Avantis, NYSE: SNY), and Upjohn (now Pfizer, NYSE: PFE).

About Global Health Ventures Inc.

Global Health Ventures Inc. (the "Company") is a Specialty Pharma with focus on the Over-The-Counter market. The Company has a new proprietary platform technology that delivers many approved drugs via the sublingual (under the tongue) route. This unique method delivers low dose drugs directly to the blood stream, bypassing all the side effects of digestive and liver system breakdowns, while maintaining product efficacy. The Company currently has five products in late stage development and several more underway.

Safe Harbor Statement

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.

Market News and Data brought to you by Benzinga APIs